136 related articles for article (PubMed ID: 18063021)
1. Expression and activity of taxane-metabolizing enzymes in ovarian tumors.
DeLoia JA; Zamboni WC; Jones JM; Strychor S; Kelley JL; Gallion HH
Gynecol Oncol; 2008 Feb; 108(2):355-60. PubMed ID: 18063021
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.
Gréen H; Söderkvist P; Rosenberg P; Mirghani RA; Rymark P; Lundqvist EA; Peterson C
Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):130-7. PubMed ID: 19143748
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
4. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.
Bergmann TK; Gréen H; Brasch-Andersen C; Mirza MR; Herrstedt J; Hølund B; du Bois A; Damkier P; Vach W; Brosen K; Peterson C
Eur J Clin Pharmacol; 2011 Jul; 67(7):693-700. PubMed ID: 21327421
[TBL] [Abstract][Full Text] [Related]
5. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer.
Yamaguchi H; Hishinuma T; Endo N; Tsukamoto H; Kishikawa Y; Sato M; Murai Y; Hiratsuka M; Ito K; Okamura C; Yaegashi N; Suzuki N; Tomioka Y; Goto J
Int J Gynecol Cancer; 2006; 16(3):979-85. PubMed ID: 16803472
[TBL] [Abstract][Full Text] [Related]
6. Xiaoaiping injection enhances paclitaxel efficacy in ovarian cancer via pregnane X receptor and its downstream molecules.
Zhang XQ; Ding YW; Chen JJ; Xiao X; Zhang W; Zhou L; Kong QW; Shi MZ; Yang J; Jiang B; Guo C; Han YL
J Ethnopharmacol; 2020 Oct; 261():113067. PubMed ID: 32505840
[TBL] [Abstract][Full Text] [Related]
7. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.
Fransson MN; Gréen H; Litton JE; Friberg LE
Drug Metab Dispos; 2011 Feb; 39(2):247-55. PubMed ID: 21056987
[TBL] [Abstract][Full Text] [Related]
8. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
Henningsson A; Marsh S; Loos WJ; Karlsson MO; Garsa A; Mross K; Mielke S; Viganò L; Locatelli A; Verweij J; Sparreboom A; McLeod HL
Clin Cancer Res; 2005 Nov; 11(22):8097-104. PubMed ID: 16299241
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes.
van Eijk M; Boosman RJ; Schinkel AH; Huitema ADR; Beijnen JH
Cancer Chemother Pharmacol; 2019 Sep; 84(3):487-499. PubMed ID: 31309254
[TBL] [Abstract][Full Text] [Related]
10. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship.
Cresteil T; Monsarrat B; Dubois J; Sonnier M; Alvinerie P; Gueritte F
Drug Metab Dispos; 2002 Apr; 30(4):438-45. PubMed ID: 11901098
[TBL] [Abstract][Full Text] [Related]
11. Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel.
Nallani SC; Genter MB; Desai PB
Cancer Chemother Pharmacol; 2001 Aug; 48(2):115-22. PubMed ID: 11561777
[TBL] [Abstract][Full Text] [Related]
12. Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4.
Taniguchi R; Kumai T; Matsumoto N; Watanabe M; Kamio K; Suzuki S; Kobayashi S
J Pharmacol Sci; 2005 Jan; 97(1):83-90. PubMed ID: 15655291
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers.
Jiko M; Yano I; Sato E; Takahashi K; Motohashi H; Masuda S; Okuda M; Ito N; Nakamura E; Segawa T; Kamoto T; Ogawa O; Inui K
Int J Clin Oncol; 2007 Aug; 12(4):284-90. PubMed ID: 17701008
[TBL] [Abstract][Full Text] [Related]
14. 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.
de Graan AJ; Sparreboom A; de Bruijn P; de Jonge E; van der Holt B; Wiemer EA; Verweij J; Mathijssen RH; van Schaik RH
Br J Clin Pharmacol; 2015 Sep; 80(3):560-8. PubMed ID: 26119961
[TBL] [Abstract][Full Text] [Related]
15. Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.
Bergmann TK; Brasch-Andersen C; Gréen H; Mirza MR; Skougaard K; Wihl J; Keldsen N; Damkier P; Peterson C; Vach W; Brøsen K
Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):199-204. PubMed ID: 21955855
[TBL] [Abstract][Full Text] [Related]
16. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer.
Chen Y; Bieber MM; Teng NN
Mol Carcinog; 2014 Aug; 53(8):625-34. PubMed ID: 23423781
[TBL] [Abstract][Full Text] [Related]
17. Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8.
García-Martín E; Pizarro RM; Martínez C; Gutierrez-Martín Y; Pérez G; Jover R; Agúndez JA
Pharmacogenomics; 2006 Jun; 7(4):575-85. PubMed ID: 16753005
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporine markedly raises the plasma concentrations of repaglinide.
Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
[TBL] [Abstract][Full Text] [Related]
19. Should we be using cimetidine to premedicate patients receiving docetaxel or paclitaxel?
Clouse T; Geisler JP; Manahan KJ; Gudenkauf TJ; Linnemeier G; Wiemann MC
Gynecol Oncol; 2004 Oct; 95(1):270-1. PubMed ID: 15385146
[No Abstract] [Full Text] [Related]
20. Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells.
Martin P; Riley R; Back DJ; Owen A
Br J Pharmacol; 2008 Feb; 153(4):805-19. PubMed ID: 18037906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
